Cancer preventive agents. 7. Antitumor-promoting effects of seven active flavonolignans from milk thistle (Silybum marianum) on Epstein-Barr virus activation

Pharmaceutical Biology

Volumn 45, Issue 10, 2007, Pages 735-738

  Lin, An Shen ^a   Shibano, Makio ^a   Nakagawa Goto, Kyoko ^a   Tokuda, Harukuni ^b   Itokawa, Hideji ^a   Morris Natschke, Susan L ^a   Lee, Kuo Hsiung ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Antitumor promotors; Cancer preventive agents; Flavonolignans; Milk thistle; Silybum marianum; Silymarin

Indexed keywords

BETA CAROTENE; EPSTEIN BARR VIRUS ANTIGEN; FLAVONOID; FLAVONOLIGNAN; ISOSILYBIN A; ISOSILYBIN B; PHORBOL 13 ACETATE 12 MYRISTATE; SILIBININ A; SILIBININ B; SILICRISTIN; SILICRISTIN A; SILICRISTIN B; SILIDIANIN; SILYBUM MARIANUM EXTRACT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; DRUG INHIBITION; DRUG SCREENING; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; RAJI CELL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SILYBUM MARIANUM; VIRUS ACTIVATION;

ASTERACEAE; HUMAN HERPESVIRUS 4; SILYBUM MARIANUM;

EID: 36749029366     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880200701585592     Document Type: Article

References (18)

1. Aggarwal BB, Shishodia S (2006): Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1421.
2. Ball KR, Kowdley KV (2005): A review of Silybum marianum (milk thistle) as a treatment for alcoholic liver disease. J Clin Gastroenterol 39: 520-528.
3. Bhatia N, Zhao J, Wolf DM, Agarwal R (1999): Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: Comparison with silymarin. Cancer Lett 147: 77-84.
4. Crocenzi FA, Roma MG (2006): Silymarin as a new hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Curr Med Chem 13: 1055-1074.
5. Dhiman RK, Chawla YK (2005): Herbal medicines for liver diseases. Dig Dis Sci 50: 1807-1812.
6. Flaig TW, Gustafson DL, Su L-J, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glode LM (2007): A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 25: 139-146.
7. Flora K, Hahn M, Rosen H, Benner K (1998): Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93: 140-143.
8. Henle G, Henle W (1966): Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 91: 1248-1256.
9. Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence V (2002): Milk thistle for the treatment of liver disease: A systematic review and meta-analysis. Am J Med 113: 506-515.
10. Katiyar S (2005): Silymarin and skin cancer prevention: Anti-inflammatory, antioxidant and immunomodulatory effects (review). Int J Oncol 26: 169-176.
11. Lee DY-W, Liu Y (2003): Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod 66: 1171-1174.
12. Luper S (1998): A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 3: 410-421.
13. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C (2005): Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 100: 2583-2591.
14. Singh RP, Agarwal R (2005): Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 41: 1969-1979.
15. Smith WA, Lauren DR, Burgrss EJ, Perry NB, Martin RJ (2005): A silychristin isomer and variation of flavonolignan levels in milk thistle (Silybum marianum) fruits. Planta Med 71: 877-880.
16. Suzuki M, Nakagawa-Goto K, Nakamura S, Tokuda H, Morris-Natschke SL, Kozuka M, Nishino H, Lee K-H (2006): Cancer preventive agents. Part 5. Anti-tumor-promoting effects of coumarins and related compounds on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. Pharm Biol 44: 178-182.
17. Takasaki M, Konoshima T, Fujitani K, Yoshida A, Nishimura H, Tokuda H, Nishino H, Iwashima A, Kozuka M (1990): Inhibitors of skin-tumor promotion. VIII. Inhibitory effects of euglobals and their related compounds on Epstein-Barr virus activation. (1). Chem Pharm Bull 38: 2737-2739.
18. Wang X, Nakagawa-Goto K, Kozuka M, Tokuda H, Nishino H, Lee K-H (2006): Cancer preventive agents. Part 6: Chemopreventive potential of furanocoumarins and related compounds. Pharm Biol 44: 116-120.